First Time Loading...
H

Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267

Watchlist Manager
Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267
Watchlist
Price: 2.4 CNY Market Closed
Updated: Jun 3, 2024
Section:
 

Relative Value

The Relative Value of one Hunan Er-Kang Pharmaceutical Co Ltd stock under the Base Case scenario is 2.19 CNY. Compared to the current market price of 2.4 CNY, Hunan Er-Kang Pharmaceutical Co Ltd is Overvalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
2.19 CNY
Overvaluation 9%
Relative Value
Price
H
Worst Case
Base Case
Best Case

Valuation Multiples

3.3
P/S
P/S
Price to Sales
3.3
vs History
76
vs Industry
36
Median 3Y
3.5
Median 5Y
3.7
Industry
2.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
2
Median 3Y
33.3
Median 5Y
56.9
Industry
22.4
More Details
17.5
P/OCF
P/OCF
Price to OCF
17.5
vs History
87
vs Industry
25
Median 3Y
36.4
Median 5Y
36.4
Industry
16.9
More Details
25
P/FCFE
P/FCFE
Price to FCFE
25
vs History
36
vs Industry
19
Median 3Y
-29.5
Median 5Y
-21.3
Industry
22.6
More Details
1
P/B
P/B
Price to Book Value
1
vs History
96
vs Industry
61
Median 3Y
1.4
Median 5Y
1.4
Industry
2
More Details
3.2
EV/S
EV/S
Enterprise Value to Sales
3.2
vs History
71
vs Industry
36
Median 3Y
3.4
Median 5Y
3.4
Industry
2.5
More Details
15.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
15.6
vs History
42
vs Industry
12
Median 3Y
15.6
Median 5Y
14.6
Industry
5.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
0
Median 3Y
-6.9
Median 5Y
46.8
Industry
13.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
0
Median 3Y
-6.9
Median 5Y
46.8
Industry
16.6
More Details
17
EV/OCF
EV/OCF
Enterprise Value to OCF
17
vs History
87
vs Industry
26
Median 3Y
35.3
Median 5Y
35.3
Industry
15.7
More Details
101.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
101.3
vs History
17
vs Industry
5
Median 3Y
-32.1
Median 5Y
-34.8
Industry
17.7
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
96
vs Industry
58
Median 3Y
1.4
Median 5Y
1.4
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Hunan Er-Kang Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267
5B CNY 3.3 -22.7 -20.3 -20.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
779.7B USD 21.7 127 62.1 70.7
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK 16.8 45.9 34.2 37.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
353B USD 4.1 9.2 11.3 14.8
US
Merck & Co Inc
NYSE:MRK
318B USD 5.2 137.9 34.4 56.2
UK
AstraZeneca PLC
LSE:AZN
189.3B GBP 5.1 38.1 174.7 278.7
CH
Roche Holding AG
SIX:ROG
185.6B CHF 3.2 16.1 9.2 10.9
CH
Novartis AG
SIX:NOVN
182.1B CHF 3.4 11.5 8.8 12.8
US
Pfizer Inc
NYSE:PFE
162.4B USD 2.9 -525.6 12.7 20.6
P/E Multiple
Earnings Growth
CN
H
Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267
Average P/E: 55.1
Negative Multiple: -22.7 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
127
364%
DK
Novo Nordisk A/S
CSE:NOVO B
45.9
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.2
-21%
US
Merck & Co Inc
NYSE:MRK
137.9
7 598%
UK
AstraZeneca PLC
LSE:AZN
38.1
175%
CH
Roche Holding AG
SIX:ROG
16.1
28%
CH
Novartis AG
SIX:NOVN
11.5
17%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -525.6
683%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 143,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.